Drug Trial Radar · NCT00283946
A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia
Last checked: Nov 19, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
876
Actual
Start
Feb 2006
Primary completion
Nov 2007
Study completion Nov 2007
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 31, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) in patients with insomnia by a randomized, double-blind, group-comparison study using zolpidem (Myslee) as a comparative drug
Conditions
- Sleep Initiation and Maintenance Disorders
- Sleep Disorders
Interventions
Zolpidem MRDrug
Oral
ZolpidemDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean wake time after sleep onset during the double-blind periodTime frame: 2 Weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chubu Region, Japan
Site not named
Chugoku Region, Japan
Site not named
Hokkaido Region, Japan
Site not named
Kansai Region, Japan
Site not named
Kanto Region, Japan
Site not named
Kyushu Region, Japan
Site not named
Shikoku Region, Japan
Site not named
Tohoku Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.